Kallio M, Haapaniemi T, Turkka J, Suominen K, Tolonen U, Sotaniemi K, Heikkil VP, Myllyl V (2000) Heart rate variability in patients with untreated Parkinsons disease
SOURCE: The Wall Street Journal , April 1, 2025 Copyright 2025 HealthDay
KPV's small size (~340 Da) supports tissue penetration research and is studied in combination formulations for multi-pathway anti-inflammatory endpoint experiments
Founder with vision and experience Catharine Arnston transitioned from the corporate world to nutrition in response to a health challenge in the family
Gasdermin-D pores induce an inactivating caspase-4 cleavage that limits IL-18 production in the intestinal epithelium
Lilly's next-gen Triple G (GLP-1/GIP/glucagon) agonist (Phase 1b, Phase 2): started recruiting for a Phase 3 trial this year approvals are expected by 2026